Jacobio Pharmaceuticals Group Co., Ltd. (HK:1167) has released an update.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Jacobio Pharmaceuticals has reached a significant milestone by completing the first patient dosage in the Phase I/IIa clinical trial of its pan-KRAS inhibitor, JAB-23E73, in China. This innovative oral drug aims to target KRAS mutations found in a substantial percentage of cancer patients worldwide, with promising preclinical results. Investors may find Jacobio’s continued advancement in drug development noteworthy as the company strives for global leadership in innovative cancer treatments.
For further insights into HK:1167 stock, check out TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue